[go: up one dir, main page]

MX2020011993A - Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. - Google Patents

Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Info

Publication number
MX2020011993A
MX2020011993A MX2020011993A MX2020011993A MX2020011993A MX 2020011993 A MX2020011993 A MX 2020011993A MX 2020011993 A MX2020011993 A MX 2020011993A MX 2020011993 A MX2020011993 A MX 2020011993A MX 2020011993 A MX2020011993 A MX 2020011993A
Authority
MX
Mexico
Prior art keywords
methods
rheumatoid arthritis
compositions
treatment
same
Prior art date
Application number
MX2020011993A
Other languages
English (en)
Inventor
Xiaohong Huang
Martine Jasson
Vanessa Marks
Allen Radin
Chungpeng Fan
Hoogstraten Hubert Van
Stefano Fiore
Mark Genovese
Adelsberg Janet Van
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2020011993A publication Critical patent/MX2020011993A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y métodos de tratamiento y alivio de los síntomas de la artritis reumatoide usando un anticuerpo que se une especificamente al receptor de interleuquina-6 humana (hIL-6R).
MX2020011993A 2013-11-22 2016-05-20 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. MX2020011993A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US201462008787P 2014-06-06 2014-06-06
EP14306366 2014-09-05

Publications (1)

Publication Number Publication Date
MX2020011993A true MX2020011993A (es) 2021-01-29

Family

ID=51518724

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006595A MX377190B (es) 2013-11-22 2014-11-21 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
MX2020011993A MX2020011993A (es) 2013-11-22 2016-05-20 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016006595A MX377190B (es) 2013-11-22 2014-11-21 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Country Status (11)

Country Link
US (1) US20160280782A1 (es)
EP (2) EP3071230B1 (es)
JP (3) JP6657089B2 (es)
KR (3) KR20230155586A (es)
CN (2) CN106413748A (es)
AU (3) AU2014352801B2 (es)
CA (1) CA2930615C (es)
MX (2) MX377190B (es)
PL (1) PL3071230T3 (es)
SG (1) SG10201804000TA (es)
WO (1) WO2015077582A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
CN106413748A (zh) * 2013-11-22 2017-02-15 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法
KR20180073680A (ko) 2015-11-03 2018-07-02 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 포도막염 및 황반 부종의 치료를 위한 il6r 항체를 포함하는 조성물 및 이를 이용하는 방법
KR20230093522A (ko) * 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
US12295912B2 (en) 2017-12-07 2025-05-13 Zacros Corporation Port-equipped bag and cap-equipped bag
MX2021002422A (es) * 2018-08-29 2021-07-15 Regeneron Pharma Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
TW202521583A (zh) * 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
TW202106712A (zh) * 2019-04-24 2021-02-16 美商再生元醫藥公司 類風溼性關節炎之診斷及治療方法
MA56116A (fr) 2019-06-04 2022-04-13 Stefano Fiore Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN106413748A (zh) * 2013-11-22 2017-02-15 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法
ES2799439T3 (es) * 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas

Also Published As

Publication number Publication date
AU2024204881A1 (en) 2024-08-15
SG10201804000TA (en) 2018-07-30
JP6657089B2 (ja) 2020-03-04
CA2930615A1 (en) 2015-05-28
EP3071230A1 (en) 2016-09-28
CN106413748A (zh) 2017-02-15
AU2014352801B2 (en) 2020-05-28
JP2016539125A (ja) 2016-12-15
WO2015077582A1 (en) 2015-05-28
KR20230155586A (ko) 2023-11-10
CN120514847A (zh) 2025-08-22
CA2930615C (en) 2023-04-04
PL3071230T3 (pl) 2020-09-21
JP2022033891A (ja) 2022-03-02
AU2020223706A1 (en) 2020-09-10
KR20220056254A (ko) 2022-05-04
EP3770173A1 (en) 2021-01-27
KR20160079121A (ko) 2016-07-05
AU2014352801A1 (en) 2016-06-23
US20160280782A1 (en) 2016-09-29
AU2020223706B2 (en) 2024-04-18
MX2016006595A (es) 2016-09-06
JP2024026223A (ja) 2024-02-28
EP3071230B1 (en) 2020-04-08
MX377190B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
PH12014500784B1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
MY191169A (en) Anti-fcrh5 antibodies
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
MX2020002289A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2015013901A (es) Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
NZ707086A (en) Anti-cd40 antibodies and methods of use
IN2014DN05885A (es)
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
EA201592203A1 (ru) Способы лечения таупатии
JO3607B1 (ar) مضادات الأجسام المضادة لإنترفيرون ألفا وأوميجا
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
MX2021010472A (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
MY188405A (en) Anti-cd154 antibodies and methods of using them
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
SG10201807059QA (en) Agents for influenza neutralization
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
MX2016002027A (es) Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos.
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка